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HER-2/neu may play a role in prostate carcinogenesis. The aim of this study was to use the expression of HER-2/neu as a molecular
marker for the detection of circulating tumour cells (CTCs) in the blood of patients with prostate cancer (PC). Blood samples were
collected from 42 patients with PC and nine healthy volunteers. Immunomagnetic beads were used to harvest epithelial cells from
peripheral blood mononuclear cells. Total RNA was extracted and reverse transcribed before analysis by real-time PCR with HER-2/
neu-specific primers. CTCs were HER-2/neu positive in six out of 11 (54%) patients with metastatic disease and in three out of 31
(9.6%) patients with localised PC (P¼0.004). In blood samples from nine healthy volunteers, we detected no expression of HER-2/
neu. The present method appears to be minimally invasive, highly sensitive and a specific approach for detecting CTCs in PC.
Furthermore, it may help better target HER-2/neu in advanced PC.
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Prostate cancer (PC), the most common cancer in men in western
countries, presents a dynamic process in which different clinical
and biological phases in both the natural and treated history of the
disease may be characterised (Scher and Heller, 2000). The
pathways that underlie tumour progression, invasion and resis-
tance to treatment in each clinical state are being increasingly
understood, and novel biologic agents that target these pathways
are in development or are now available for clinical testing. On the
other hand, establishment of new biomarkers is needed to identify
high-risk patients as candidates for new (adjuvant) therapies and
to find new surrogate endpoints to assess the efficacy of these
treatments (De Marzo et al, 2001).
Among serum markers of prostate carcinogenesis, the detection
of circulating tumour cells (CTCs) by RT-PCR for prostate-specific
antigen (PSA) and prostate-specific membrane antigen (PSMA)
mRNA proved to be positive in both peripheral blood and bone
marrow (BM). The level of CTCs detected in this setting ranges
from 0 to 72% in patients with clinically organ confined (T1-2)
disease and from 25 to 100% in patients with distant metastases
(Israeli et al, 1994; Katz et al, 1994; Ghossein et al, 1995; Seiden
et al, 1995; Sokoloff et al, 1996; Corey et al, 1997; Wood and
Banerjee, 1997; Mejean et al, 2000; Hara et al, 2002). However, the
major question of the specificity of the RT-PCR approach remains
unanswered because of illegitimate transcripts in lymphocytes or
other blood cells.
The detection of CTCs using more specific markers such as
overexpression of HER-2/neu may be more attractive.
The HER-2/neu oncogene is located on chromosome 17q21
and it encodes a 185kDa transmembrane tyrosine kinase receptor
of the epidermal growth factor receptor family (Schechter et al,
1985; Yamamoto et al, 1986). Amplification of the HER-2/neu
gene and/or overexpression of the protein are found in a variety
of human cancers and a number of clinical studies have attempted
to correlate its presence with poor patient prognosis (Hynes,
1993; Hynes and Stern, 1994). In breast cancer, HER-2/neu
amplification or overexpression, according to standardised
criteria, has been described as a marker predicting both
response to treatment and poor prognosis with nodal metastases
(Slamon et al, 1987; Menard et al, 2000; Yamauchi et al, 2001).
Targeting HER-2 using a humanised monoclonal anti-
body (trastuzumab, Herceptine
s) in combination with chemo-
therapy confers a survival benefit for patients with metastatic
breast carcinoma that overexpress HER-2 (Slamon et al, 2001),
raising the possibility of therapeutic benefits for other types
of malignancies that similarly express HER-2. Although the
assessment of HER-2/neu overexpression in PC varies widely due
to procedural differences, evidence suggests that HER-2/neu may
be important in cancer progression (Signoretti et al, 2000).
Antitumour activity of anti-HER-2/neu antibody was shown in
both androgen-dependent and -independent human xenograft
models (Agus et al, 1999). Preliminary clinical trials of trastuzu-
mab have been performed in metastatic PC (Small et al, 2001;
Morris et al, 2002). The results of these trials underscored
the requirement to better access HER-2/neu expression in
order to identify subgroups of patients who may benefit from
HER-2/neu targeting.
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yThe aim of the present study was to use the expression of
HER-2/neu as a molecular marker for the detection of cancer
cells in the blood of 42 patients with PC and various clinical stages.
Indeed, compared to other molecular markers (e.g. PSA), HER-2/
neu has several advantages: it plays a role in prostate tumour
progression, and it represents a potential therapeutic target since a
commercially available antibody exists and has been successfully
tested in the setting of breast cancer. In addition, overexpression of
HER-2/neu is highly specific for cancer cells and has never being
reported in the blood cells. Therefore, the use of HER-2/neu avoids
the problem related to illegitimate transcripts in lymphocytes or
other blood cells.
MATERIALS AND METHODS
Patients
A total of 42 men, aged 54–81 years, with histologically confirmed
PC were included in this study. Blood samples were collected
before any treatment in patients with localised PC and during
hormone therapy in patients with metastases. All the blood
samples were taken at an interval from any biopsy or digital
examination. For patients who underwent surgery, blood was
collected the day before the surgical procedure. According to
clinical status and treatment, patients were divided into two
groups: 11 patients with distant metastasis receiving hormone
therapy (group 1) and 31 patients with localised PC (group 2).
Among patients with localised PC (n¼31), 18 were treated by
radical prostatectomy (patient no. 12–29) and 13 by radiation
(patient nos. 30–42) (see Tables 1 and 2). For surgically treated
patients, localised PC was defined histologically (pT). For patients
treated by radiation therapy, PC was clinically and radiologically
defined. All these patients underwent endorectal coil MRI, in order
to rule out extracapsular or seminal vesicules invasion. Nine
healthy male volunteers, aged 34–60 years, were selected as a
negative control group.
Blood samples and immunomagnetic separation of
circulating epithelial cells
Blood samples (20ml) were collected in heparinised tubes and
stored at 41C for a maximum of 2h before the experiments.
Epithelial cells were separated as described by Soria et al, 1999.
Hypaque and resuspended in 1ml of PBS-2% FCS. Then, 12.5 10
6
prewashed immunomagnetic beads covalently coated with the
BerEP4 monoclonal antibody (Dynal A.S., Oslo, Norway) were
added. BerEP4 monoclonal antibody recognises an epitope on the
protein moiety of 2 glycopeptides (34 and 39kDa) expressed at the
surface of epithelial cells in normal and malignant tissues (Latza
et al, 1990). Following incubation at 41C for 30min, cells bound to
the beads were harvested using a magnetic field. The harvested
epithelial cells (HECs) were then washed six times with PBS–2%
FCS. Washing efficiency was controlled by microscopic examina-
tion to verify that the samples only contained immunomagnetic
bead-coated cells. Cells and beads were then stored at  801Ci n
two Eppendorf tubes for PCRs.
RNA extraction
RNA was extracted from cells using the commercially available kit
(RNeasy 74104, Qiagen, Hilden, Germany). Samples were stored at
 801C for up to 4 weeks before the assay.
cDNA synthesis
The detection of HER-2/neu mRNA was performed in a two-step
procedure as described by the LightCycler HER-2/neu RNA
Table 1 Clinical, pathological and biological status of 11 patients with
metastatic prostate carcinoma
a (group 1)
Circulating
tumour cells
Patient
no. Age
Score of
gleason M
Plasmatic
marker:
PSA
b,c Treatment
Status HER-2/neu:
RT-PCR
(LightCycler)
17 9 2 + 1 5 H T  
2 67 7 + 0.8 HT +
36 7 7 + 8 8 H T +
4 79 7 + 0.9 HT  
5 74 7 + 2.38 None +
6 74 4 + 0.1 HT  
7 81 4 + 2.9 HT +
8 72 7 + 3.1 HT  
9 68 7 + 82.3 HT  
10 78 5 + 508 HT +
11 80 4 + 492 HT +
aHT¼hormonotherapy; CTC¼circulating tumour cell; PSA¼prostate-specific
antigen.
bNormal value for PSA: o5ngml
 1.
cPSA kit (Kryptor-PSA, Brahms,
Germany).
Table 2 Clinical, pathological and biological status of 31 patients with
localised prostate carcinoma
a before radical prostatectomy (patients 12–
29) and before treatment by radiation therapy (patients 30–42)
Circulating
tumour cells
Patient
no. Age
Score of
gleason T N M
Plasmatic
marker:
PSA
b
Status HER-2/neu:
RT-PCR
(LightCycler)
12 62 6 2b X 0 16.3  
13 74 7 3b 1 0 17.9  
14 68 5 2a X 0 8  
15 66 5 3a X 0 8.8  
16 79 6 3a X 0 12.2  
17 64 7 2a X 0 9.1  
18 67 5 2b X 0 5.9  
19 69 6 2b X 0 13.3  
20 62 7 3b X 0 12.5  
21 60 6 2b X 0 7.1  
22 76 6 2b X 0 11  
23 72 6 2a X 0 7  
24 62 6 2b X 0 0.9  
25 66 9 3b X 0 8.5  
26 57 7 3b X 0 8.2  
27 78 9 3b X 0 6.3  
28 65 5 2b X 0 2.6  
29 55 6 2b 0 0 33  
30 78 2 1c 0 0 6.4  
31 67 7 1c 0 0 6  
32 74 5 1c 0 0 10  
33 74 5 2a 0 0 7  
34 63 6 2a 0 0 35 +
35 58 3 2a 0 0 10  
36 75 7 2a 0 0 9  
37 74 7 1c 0 0 13 +
38 54 6 1c 0 0 10.6  
39 58 6 1c 0 0 5.9 +
40 57 8 2a 0 0 20  
41 61 8 2a 0 0 8.9  
42 66 5 1c 0 0 5  
aHT¼hormonotherapy; ND¼not determined; PSA¼prostate-specific antigen.
bNormal value for PSA: o5ngml
 1.T ¼pT for patients 12–29, T¼clinical and
radiological results for patients 30–42; N¼pN for patients 12–29, N¼clinical and
radiological results for patients 30–42; M¼radiological results.
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yQuantification Kit (Roche). Briefly, in the first step, cDNA was
prepared from RNA by reverse transcription in a final volume of
20ml in a thermal cycler (PTC-200, MJ Research). The samples
were incubated at 251C for 10min, and then 421C for 60min and
941C for 5min. cDNA were stored at  201C.
PCR conditions
In the second step, a 395bp fragment of HER-2/neu mRNA was
amplified from cDNA by PCR using specific primers (LightCycler-
HER2/neu RNA Quantification Kit, Roche, Mannheim, Germany).
The amplicon was detected by fluorescence using a specific pair of
Hybridisation Probes consisting of two different oligonucleotides
labelled at the 50-end with LightCycler-Red 640 and at the 30-end
with LightCycler-Fluorescein. Only after hybridisation to the
template DNA do the two probes come in close proximity,
resulting in fluorescence resonance energy transfer (FRET)
between the two fluorophores measured by the LightCycler
instrument. The kit included a calibrator containing a stabilised
fraction of total RNA purified from an immortalised cell line
constitutively expressing HER-2/neu. The efficiency of PCR was
assessed with serial dilutions of this calibrator in each run. For
quantification, crossing point (Cp) was used, the cycle at which
PCR amplification begins its exponential phase and is considered
the point most reliably proportional to initial concentration. The
amount of mRNA encoding for HER-2/neu is expressed as a
relative ratio to a reference gene (G6PDH) in a sample relative to
the Her-2/neu:G6PDH ratio in a calibrator.
Of the total reverse transcription volume of 20ml, 4ml was used
for each PCR. The polymerase amplification was performed in a
total volume of 10ml. Each experiment was performed in duplicate.
The thermal cycling conditions were: denaturation for 20min at
951C followed by amplification 10s at 951C, then 15s at 651C and
15s at 721C for 50 cycles, terminated by a cooling step 30s at 401C.
RESULTS
Determination of assay sensitivity
We analysed the sensitivity of the present method by serial
dilutions of SK-BR-3 cell line, which is used as a reference
for overexpression of HER-2/neu (Pergram et al, 1997). The
lower limit of detection was that of p1 cellml
 1 of blood
(Figure 1).
Detection of HER-2/neu transcripts in CTCs in the blood of
healthy volunteers
In blood samples from nine healthy volunteers, we detected no
expression of HER-2/neu.
Detection of HER-2/neu transcripts in CTCs in the blood of
patients with PC
Group 1 (metastatic PC) Group 1 included 11 patients with
metastatic PC. The median age of these patients was 74 years
(range, 67–81). Of these 11 patients, six (54%) were positive for
the detection of HER-2/neu.
Group 2 (localised PC) Group 2 included 31 patients with
T1c-T3b PC from whom blood was collected before treatment by
radical prostatectomy or radiation therapy. The median age was
66.5 years (range, 54–79). Of these 31 patients, three (9.6%) were
positive for the detection of HER-2/neu.
Tables 1 and 2 summarise the biological, clinical and
pathological status of patients at sampling time.
The specific association of HER-2/neu transcripts with the
presence of epithelial cells in patients with PC was demonstrated
by the absence of contaminating lymphocytes in HEC samples.
The washing efficiency and lack of lymphocytic contamination
were controlled for each sample by microscopic examination
to verify that samples only contained immunomagnetic bead-
coated cells (Figure 2 shows an example of this cytologic analysis
from patient #34).
We studied the relationship of HER-2/neu positivity in CTCs of
patients with different clinical status. The rate of HER-2/neu
detection in CTCs of patients with metastatic PC was significantly
higher than that of patients with localised disease (Fisher’s exact
test, P¼0.004) (see Table 3).
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Figure 1 Expression of HER-2/neu RNA by real-time PCR (LightCycler). Amplification curve shows serial dilutions of an initial amount of SK-BR-3 RNA: 1
(3333 cells), 2 (333 cells), 3 (166 cells), 4 (33 cells), 5 (16 cells), 6 (1.6 cells) and 7 (0.6 cells). Inset, standard curve plot of the log of SK-BR-3 RNA cells
numbers vs Cp. The standard curve shows seven orders of linear dynamic range (y¼ 3.67xþ33.071; R
2¼0.9983).
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RT-PCR of several prostate-related genes (PSA, PSMA) as well as
immunohistochemical assays (PSA, CK 18) have been used to
detect circulating PC cells, but none of these techniques is
currently applied in the clinical setting. To our knowledge, HER-
2/neu has not been used for detecting CTCs from PC. In the
present study, we have combined immunomagnetic separation of
circulating epithelial cells with RT-PCR detection of the HER-2/
neu transcripts, in order to increase the specificity and better
characterise the molecular profile of CTCs. Nevertheless, the
complexity of the present technique should be kept in mind, if its
implementation in clinical practice is envisioned. Furthermore, it
is important to highlight that the present procedure cannot ensure
that the circulating cancer cells detected are PC cells. Indeed, such
CTC could be from another epithelial cancer expressing Her2/neu
(e.g. bladder cancer). Nevertheless, this is not a frequent clinical
situation, especially in patients with radiological and clinical
follow-ups.
Evidence suggests that co-operative signalling via c-erbB
receptors (such as, HER-1, HER-2/neu, HER-3 and HER-4) can
regulate many key processes such as angiogenesis and invasion in
most cancers (Eccles, 2001; O-charoenrat et al, 2002). In vitro,
HER-2/neu induced metastatic capacities, when it was transfected
into a PC cell line (Zhau et al, 1999). When evaluated by
immunohistochemistry (IHC), HER-2/neu expression varies lar-
gely from one study to another because of methodologic
differences and heterogeneity of PC (Gu et al, 1996; Lara et al,
2002). The published incidence of HER-2/neu overexpression is
typically in the range of 25–40% and 60–80%, respectively, in
localised PC (Sadasivan et al, 1993; Ross et al, 1997; Fossa et al,
2002) and in metastatic PC (Osman et al, 2001; Morris et al, 2002).
An elevation of serum HER-2/neu was also observed for detection
of the extracellular domain of the protein by immunoradiometric
assay in patients with advanced cancer stages (Arai et al, 1997).
However, alterations in the HER-2/neu expression as a tumour
progression marker from localised to metastatic PC have yet to be
fully established. Nevertheless, in vitro and clinical studies have
linked HER-2/neu expression to the development of late androgen-
independent disease (Craft et al, 1999; Signoretti et al, 2000). These
data suggest that HER-2 overexpression would be higher if a
tumour sample can be obtained from patients with androgen-
independent disease. This is a difficult challenge, because very few
of these patients have diseases that can be biopsied readily,
because metastatic PC involve mostly the skeleton.
To date, cancer-targeting therapy by trastuzumab is only
indicated for metastatic breast cancer patients with an over-
expression of HER-2/neu by IHC (3þ), while in PC this has not
yet been evaluated.
In the present study, we evaluated the frequency of the
expression of HER-2/neu in CTCs of patients with localised PC
vs patients with metastatic PC. HER-2/neu was detected in 54% of
CTCs of patients with a metastatic disease and in 9.6% of CTCs of
patients with localised PC (P¼0.004). This result suggests a
potential value for HER-2/neu as a marker of tumour progression
even when evaluated in CTCs. Indeed, the precise phenotypic
profile of the CTCs truly responsible for clinical metastasis is not
known to date. Table 4 summarises our results as compared to
previously published manuscripts.
Among the 31 patients with localised PC, 16 patients were
classified as ‘low-risk patients’ (serum PSA p10 and Gleason score
p6) and 15 patients were classified as ‘intermediate or high-risk
patients’ (PSA: 10–20 or Gleason score¼7 and PSA 420 or
Gleason score: 8–10). One of 16 patients and two of 15 patients are
positive for the detection of HER-2/neu in these groups, retro-
spectively. To establish whether patients with localised disease and
HER-2/neu-positive CTCs are at a higher risk of recurrence will
Figure 2 Carcinoma cells isolated with BerEP4-coated immunomagnetic
beads from patient no. 34, coloration by May–Gru ¨nwald–Giemsa (CTCs
isolated from a patient with localised prostate carcinoma before treatment
by brachytherapy, this was an HER-2/neu-positive patient).
Table 3 HER-2/neu expression in CTCs of prostate cancer patients
according to clinical status
Patient characteristics
Number of
patients
Positive
cases %
Metastatic PC (group 1) 11 6(54%)
Localised PC (group 2) 31 3(9.6%)*
*P¼0.004 by Fisher exact test. CTC¼circulating tumour cell; PC¼prostate cancer.
Table 4 RT-PCR or PCR detection of CTC and BM micrometastases in
PC
RT-PCR or PCR
positive/total(%)
Author Marker Sample
Localised
PC
Metastatic
PC
Katz et al PSA mRNA Blood 25/65 (38%) 14/18 (78%)
Israeli et al PSA mRNA Blood 0/18 (0%) 6/24 (25%)
PSMA mRNA Blood 13/18 (72%) 16/24 (67%)
Seiden et al PSA mRNA Blood 3/41 (7%) 11/35 (31%)
Ghossein et al PSA mRNA Blood 4/25 (16%) 26/76 (34%)
Sokoloff et al PSA mRNA Blood 43/69 (62%) 29/33 (88%)
PSMA mRNA Blood 12/69 (17%) 13/33 (39%)
Corey et al PSA mRNA Blood 12/63 (19%) 6/13 (46%)
BM 45/63 (71%) 10/13 (77%)
Wood and Banerjee PSA mRNA BM 39/86 (45%) NA
Mejean et al PSA mRNA Blood NA 9/9 (100%)
Laribi et al Prostasin mRNA Blood 18/69 (26%) 17/27 (63%)
Hara et al PSA mRNA Blood 1/41 (2.4%) 7/14 (50%)
PSMA mRNA Blood 2/41 (4.9%) 9/14 (64%)
PSCA mRNA Blood 0/41 (0%) 7/14 (50%)
Present series HER-2/neu mRNA Blood 3/31 (9.6%) 6/11 (54%)
CTC¼circulating tumour cell; BM¼bone marrow; PC¼prostate cancer; PSA¼-
Prostate-specific antigen; PSMA¼prostate-specific membrane antigen; PSCA¼-
prostate stem cell antigen.
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primary tumours of the patient population is unfortunately not
available and will be very difficult to obtain since many patients
were referred from outside centres.
In summary, the presence of HER-2/neu in CTCs of patients
with PC is more frequent in patients with metastases than those
with localised disease. This technique may be of great assistance to
identify patients who may benefit from targeting HER-2/neu in the
clinic. In the future, additional studies should evaluate a panel of
different biomarkers in CTCs. This panel may include biomarkers
(such as MMP2, MMP9 or E-cadherine) able to better predict the
biological behaviour of CTCs (i.e. clinical metastasis). One
limitation to this approach will be the amount of CTCs and
therefore the corresponding RNA concentration available for such
studies.
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